Systemic Inactivation of TREX1 Induces Selective Inflammation of the Tumor Microenvironment and Invigorated T-cell–Mediated Tumor Control

Selective inflammation of tumor tissue and efficient tumor immune control by systemically induced loss of TREX1 support the potential efficacy and therapeutic window for treating cancer with TREX1 inhibitors.